Follow on Google News News By Tag Industry News News By Place Country(s) Industry News
Follow on Google News | Brachytherapy and ASCs - A cancer treatment program - The Ambulatory M&A AdvisorA cancer treatment program that an ASC might consider implementing and adding to the services it offers is that of brachytherapy to treat prostate cancer.
By: Ambulatory Alliances, LLC In an article published by The Ambulatory M&A Advisor, the benefits of Low Dose Rate brachytherapy to both the ASC and the patient are explained. Brachytherapy is performed by a urologist and a radiation oncologist and is an outpatient procedure that can be done in as little as one hour. Low Dose Rate Brachytherapy involves the placing of a “seed” of radioactive material directly inside the tumor. One of the major benefits of brachytherapy is that it allows the doctor to better control the radiation and decrease impact on healthy tissues. “Prostate brachytherapy requires a urologist, radiation oncologist, an anesthesiologist for day of procedure as well as a medical dosimetrist or physicist for treatment planning,” said Chief Executive Officer of Prologics Healthcare, LLC, Roger Corle. “Typically ASCs with urology participation or ownership are ideal candidates for starting a prostate brachytherapy program.” Furthermore, the equipment and licensures needed to implement a prostate brachytherapy program in an ASC are not as expensive as one might initially assume. To read the article in full, click here. The Ambulatory M&A Advisor is an online publication that covers the most up-to-date trends and topics surrounding ambulatory care center deal making, including information on investment banking in the ambulatory care sector. Contact: Blayne Rush, MHP, MBA Ambulatory Alliances, LLC 18181 Midway Rd Ste 200 Dallas, Texas 75287 469-385-7792 publisher@AmbulatoryAdvisor.com http://www.ambulatoryadvisor.com/ End
Account Email Address Disclaimer Report Abuse
|
|